295 related articles for article (PubMed ID: 20098307)
1. Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers.
Walters T; Rinehart M; Krebs W; Holdbrook M
Cornea; 2010 Mar; 29(3):263-8. PubMed ID: 20098307
[TBL] [Abstract][Full Text] [Related]
2. Tear concentrations of levofloxacin following topical administration of a single dose of 0.5% levofloxacin ophthalmic solution in healthy volunteers.
Raizman MB; Rubin JM; Graves AL; Rinehart M
Clin Ther; 2002 Sep; 24(9):1439-50. PubMed ID: 12380635
[TBL] [Abstract][Full Text] [Related]
3. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers.
Torkildsen G; O'Brien TP
Clin Ther; 2008 Nov; 30(11):2005-14. PubMed ID: 19108788
[TBL] [Abstract][Full Text] [Related]
4. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
[TBL] [Abstract][Full Text] [Related]
5. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects.
Conte JE; Golden JA; McIver M; Zurlinden E
Int J Antimicrob Agents; 2006 Aug; 28(2):114-21. PubMed ID: 16837169
[TBL] [Abstract][Full Text] [Related]
6. An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification.
Bucci FA
Am J Ophthalmol; 2004 Feb; 137(2):308-12. PubMed ID: 14962422
[TBL] [Abstract][Full Text] [Related]
7. Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes.
Akkan AG; Mutlu I; Ozyazgan S; Gök A; Yigit U; Ozüner Z; Senses V; Pekel H
Int J Clin Pharmacol Ther; 1997 May; 35(5):214-7. PubMed ID: 9174877
[TBL] [Abstract][Full Text] [Related]
8. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease.
Conte JE; Golden JA; McIver M; Little E; Zurlinden E
Int J Antimicrob Agents; 2007 Nov; 30(5):422-7. PubMed ID: 17716873
[TBL] [Abstract][Full Text] [Related]
9. Ofloxacin in human serum, urine, and tear film after topical application.
Borrmann L; Tang-Liu DD; Kann J; Nista J; Lin ET; Frank J
Cornea; 1992 May; 11(3):226-30. PubMed ID: 1587130
[TBL] [Abstract][Full Text] [Related]
10. Tear concentrations of topically applied ciprofloxacin.
Limberg M; Buggé C
Cornea; 1994 Nov; 13(6):496-9. PubMed ID: 7842707
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: an open-label, randomized, two-period crossover comparison in healthy Mexican volunteers.
Galan-Herrera JF; Poo JL; Rosales-Sanchez O; Fuentes-Fuentes E; Cariño L; Burke-Fraga V; Namur S; Parra MG
Clin Ther; 2009 Aug; 31(8):1796-803. PubMed ID: 19808138
[TBL] [Abstract][Full Text] [Related]
12. Corneal penetration of fluoroquinolones: aqueous humor concentrations after topical application of levofloxacin 0.5% and ofloxacin 0.3% eyedrops.
Koch HR; Kulus SC; Roessler M; Ropo A; Geldsetzer K
J Cataract Refract Surg; 2005 Jul; 31(7):1377-85. PubMed ID: 16105610
[TBL] [Abstract][Full Text] [Related]
13. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
14. Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.
Marier JF; Ducharme MP; DiMarco M; Di Spirito M; Morelli G; Tippabhotla SK; Badri N; Rampal A; Monif T
Clin Ther; 2006 Dec; 28(12):2070-80. PubMed ID: 17296463
[TBL] [Abstract][Full Text] [Related]
15. Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.
Kiser TH; Hoody DW; Obritsch MD; Wegzyn CO; Bauling PC; Fish DN
Antimicrob Agents Chemother; 2006 Jun; 50(6):1937-45. PubMed ID: 16723549
[TBL] [Abstract][Full Text] [Related]
16. Increased anterior chamber penetration of topical levofloxacin 0.5% after pulsed dosing in cataract patients.
Sundelin K; Seal D; Gardner S; Ropo A; Geldsetzer K; Lokkila J; Stenevi U
Acta Ophthalmol; 2009 Mar; 87(2):160-5. PubMed ID: 18771480
[TBL] [Abstract][Full Text] [Related]
17. Multiple-dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent.
Dagrosa EE; Verho M; Malerczyk V; de Looze S; Hajdú P; Toyodera K
Clin Ther; 1986; 8(6):632-45. PubMed ID: 3466701
[TBL] [Abstract][Full Text] [Related]
18. The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution.
Fukuda M; Inoue A; Sasaki K; Takahashi N
Jpn J Ophthalmol; 2004; 48(2):93-6. PubMed ID: 15060787
[TBL] [Abstract][Full Text] [Related]
19. Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration.
Healy DP; Holland EJ; Nordlund ML; Dunn S; Chow C; Lindstrom RL; Hardten D; Davis E
Cornea; 2004 Apr; 23(3):255-63. PubMed ID: 15084858
[TBL] [Abstract][Full Text] [Related]
20. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
Noel GJ; Goodman DB; Chien S; Solanki B; Padmanabhan M; Natarajan J
J Clin Pharmacol; 2004 May; 44(5):464-73. PubMed ID: 15102866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
